## The Week in Health Tech

The Week in Health Tech

Roche's $750 million acquisition of PathAI, a Boston-based digital pathology AI firm, anchors the week—the deal could reach $1.05 billion if certain clinical and commercial milestones are met. <cite index="1-1,1-3">Roche will pay $750 million upfront and additional milestone payments of up to $300 million for PathAI, a US-based company in digital pathology and AI-powered technology for pathology laboratories and the biopharma industry.</cite> The transaction caps a five-year partnership between the two organizations and signals intensifying consolidation around AI-driven companion diagnostics. Meanwhile, chronic care leader Omada Health reported strong momentum in Q1: <cite index="11-1,11-6">one year after debuting on the NASDAQ, chronic care management company Omada Health reported its first quarter 2026 earnings, with 42% year-over-year revenue growth and Q1 2026 revenue of $78 million, with a net loss of $3 million, compared to a loss of $9 million in Q1 2025.</cite> The company also crossed 1 million total members and cemented relationships with all three major pharmacy benefit managers. Regulatory enforcement intensifies this week: <cite index="61-1">the Department of Justice's new "West Coast" strike force targets Arizona, Nevada and Northern California — regions flagged for rising Medicaid, hospice and tech-enabled fraud risks.</cite> Real-world evidence for alternative care models grows stronger: <cite index="71-1,71-19">hospital at home was associated with decreased emergency department use within 30 days of discharge and lower in-hospital mortality, according to the research.</cite>

Movements

• Roche acquires PathAI for up to $1.05B to scale AI-powered diagnostics globally. <cite index="3-1,3-4">Roche has signed a deal to pay $750 million upfront for Boston-based PathAI, an acquisition by the Swiss pharmaceutical giant to speed up its use of artificial intelligence to help pathologists diagnose disease. The agreement could generate an additional $300 million for PathAI if it leads to the achievement of certain milestones.</cite> ^[1]

• BlinkLab raises AUD $17.5M ($12.6M USD) to fund FDA 510(k) pivotal trial for autism diagnostic AI. <cite index="21-2,21-3">ASX-listed diagnostics AI company BlinkLab has raised A$17.5 million ($12.6 million) through an oversubscribed placement to support regulatory and commercial work for its AI-powered diagnostic aid for autism. The proceeds will fund BlinkLab's pivotal trial of the BlinkLab Dx1 to secure the United States Food and Drug Administration's 510(k) clearance, as well as regulatory work to obtain CE marking and EU MDR compliance.</cite> ^[2]

• Dandelion Health closes $14M Series A led by Healthier Capital for multimodal clinical AI. <cite index="33-4,33-5">Dandelion Health, the clinical intelligence platform for life sciences, today announced a $14 million Series A funding round led by Healthier Capital, with participation from Colle Capital and existing investors Primary Venture Partners, Moxxie Ventures, and Convergent Ventures. The investment will accelerate Dandelion's growth across pharmaceutical drug development, deepening its data infrastructure, expanding its pharma partnerships, and bringing its platform to more research and commercial teams across the industry.</cite> ^[3]

• Rosarium Health raises $6M seed and secures Medicaid/Medicare Advantage partnerships for aging-at-home. <cite index="41-1,41-2">Rosarium Health, a company enabling aging at home, has raised $6 million in seed funding and secured partnerships with several Medicaid and Medicare Advantage plans. The seed round was led by Kalos Ventures, with support from ResilienceVC, Rock Health Capital, Symphonic Capital, American Family Insurance Institute for Corporate and Social Impact, Black Tech Nations Ventures and The Council.</cite> ^[4]

Breakthroughs & Demos

• Omada Health reports 42% YoY revenue growth and 1.02M members; joins all three major PBMs. <cite index="13-3,13-4,13-5">Omada Health, Inc. (Nasdaq: OMDA), the virtual between-visit healthcare provider, today reported financial results for the first quarter ended March 31, 2026. Total Members: 1.02 million at the end of Q1, up 51% year over year. Revenue: $78 million in the first quarter, up 42% year over year.</cite> <cite index="11-15,11-16">The company announced it is joining Eli Lilly and Company's Employer Connect program as an independent program administrator, allowing employers to offer Omada's GLP-1 Care Track alongside Lilly's obesity drug Zepbound. Last week, Omada announced it would be integrated into Optum Rx's Weight Engage pharmacy benefit manager program to help employers offer Omada's GLP-1 prescribing and lifestyle tools through their existing pharmacy benefits infrastructure.</cite> ^[5]

• Hospital-at-home programs cut in-hospital mortality to 0.4% vs 3.6% for traditional inpatient admissions. <cite index="72-9,72-10,72-11">Compared with traditional inpatient admissions, hospital-at-home patients had significantly lower odds of in-hospital mortality, researchers found. Among hospital-at-home admissions, 0.4% died in hospitals, compared to 3.6% of traditional inpatient admissions. ED utilization was also significantly lower, with 8.8% of hospital-at-home admissions visiting the ED, compared to 10% of inpatient admissions.</cite> <cite index="72-3">Hospital-at-home care has been presented as a more desirable and affordable alternative to long facility stays – and new research shows that the care model reduces in-hospital mortality and emergency department visits (ED) in the 30 days following discharge.</cite> ^[6]

• Abridge expands ambient AI documentation to nurses at 250+ health system partners nationwide. <cite index="51-2,51-4">Nurses at more than 250 of the vendor's health system clients will have access to an artificial intelligence-driven documentation tool co-developed with nurses to streamline their workflows. By automating documentation during patient encounters, the platform aims to reduce administrative burden and allow nursing staff to maintain a more direct focus on patient care.</cite> ^[7]

Blockers & Open Questions

• How will telehealth operators navigate heightened DOJ fraud enforcement across the West Coast? <cite index="61-2,61-7,61-8">Federal regulators are seeing a spike in fraud schemes that span multiple states, including controlled substance cases involving telehealth companies prescribing medications across state lines. DOJ officials stressed that the current focus is on egregious criminal conduct, such as pill mills and sham operations billing for nonexistent services — so they don't think legitimate digital health companies have much to worry about, as long as they can prove their compliance with the law. Some industry observers believe the DOJ's increasing focus on healthcare fraud could raise the compliance bar for the industry, especially in areas like telehealth and e-prescribing, where regulatory lines can be less clear and federal scrutiny is increasing.</cite> ^[8]

• Can hospital-at-home models scale equitably beyond selective patient populations? Rural adoption remains sparse and scale challenges persist despite strong clinical outcomes. <cite index="71-21">Adoption of hospital at home across the country is uneven, with few rural facilities participating.</cite> ^[9]

What to Watch Next Week

• Hims & Hers reports Q1 2026 earnings on May 11. <cite index="81-1,81-2">Hims & Hers Health, Inc. reports first quarter 2026 financial results after the market closes on Monday, May 11, 2026. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day.</cite> Analysts expect $616.9M in revenue (+5.3% YoY) but model a sharp profitability decline amid GLP-1 strategy shifts and competitive pressures. ^[10]

• ATA NEXUS 2026 opens in Orlando, May 12–14. The American Telemedicine Association's 30th annual conference assembles virtual care leaders for operational and clinical strategy discussions. ^[11]

• AMIA Clinical Informatics Conference convenes May 18–21 in Denver. The Clinical Informatics Conference co-locates with AMIA's Informatics Summit, covering AI, interoperability, and EHR innovation. ^[12]

The Numbers

Week at a glance:

• Disclosed funding announced: $50.6M (BlinkLab, Dandelion, Rosarium combined disclosed totals)
• Major M&A: Roche–PathAI, $750M upfront ($1.05B potential)
• Public earnings: Omada Health ($78M Q1 revenue, +42% YoY)
• Executive moves: None reported
• Most-discussed company: Roche (PathAI acquisition)
• Notable regulation: DOJ West Coast Health Care Fraud Strike Force expansion

Sources

This brief was generated with AI assistance, drawing on the sources cited above. See /disclosures for methodology.